派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000403 派林生物

已收盘 12-20 15:00:00

{"stockData":{"symbol":"000403","market":"SZ","secType":"STK","nameCN":"派林生物","latestPrice":20.94,"timestamp":1734678189000,"preClose":20.92,"halted":0,"volume":5104144,"delay":0,"floatShares":685000000,"shares":731000000,"eps":1.1335,"marketStatus":"已收盘","marketStatusCode":5,"change":0.02,"latestTime":"12-20 15:00:00","open":20.92,"high":21.13,"low":20.74,"amount":107000000,"amplitude":0.0186,"askPrice":20.96,"askSize":82,"bidPrice":20.94,"bidSize":322,"shortable":0,"etf":0,"ttmEps":1.1335,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":20.92,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":23.01,"lowLimit":18.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":731074913,"pbRate":1.95,"roa":"--","roe":"7.09%","epsLYR":0.8384,"committee":0.161235,"marketValue":15309000000,"floatMarketCap":14338000000,"peRate":18.473754,"changeRate":0.001,"turnoverRate":0.0075,"status":0},"requestUrl":"/m/hq/s/000403","defaultTab":"news","newsList":[{"id":"2490386290","title":"2024Q3血制品行业跟踪报告（附批签发）：进口人白批次占比提升，静丙逐季恢复","url":"https://stock-news.laohu8.com/highlight/detail?id=2490386290","media":"西南证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490386290?lang=zh_cn&edition=full","pubTime":"2024-12-12 16:11","pubTimestamp":1733991062,"startTime":"0","endTime":"0","summary":"分品种来看批签发数据，人血白蛋白：2024年前三季度，人血白蛋白批签发3797批，其中国产人白获批1229批(+9%)，占比为32.36%，进口人白获批2568批，占比为67.63%。2024Q3静丙批签发批次为355批，同比增长6%。2024Q3凝血因子Ⅷ获批127批（+1%）、凝血酶原复合物获批68批、纤维蛋白原获批101批。利润增速快于收入，主要系博雅生物非血制品业务剥离，以及天坛生物利润率同比提升等因素影响。三季度静丙院外终端价差延续。行业采浆量增长提速。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161110ab71db17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161110ab71db17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0010","BK0239","BK0168","BK0077","BK0188","BK0046","002007","BK0071","BK0028","BK0196","BK0197","BK0185","002252","600161","002880","000403","BK0082"],"gpt_icon":0},{"id":"2489637781","title":"派林生物(000403.SZ)中期每10股派1.5元 股权登记日为12月16日","url":"https://stock-news.laohu8.com/highlight/detail?id=2489637781","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489637781?lang=zh_cn&edition=full","pubTime":"2024-12-08 16:22","pubTimestamp":1733646159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)发布公告，公司将实施2024年中期利润分配，每10股派1.5元，股权登记日为12月16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2489841487","title":"派林生物(000403)11月29日股东户数2.55万户，较上期增加1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489841487","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489841487?lang=zh_cn&edition=full","pubTime":"2024-12-05 17:03","pubTimestamp":1733389426,"startTime":"0","endTime":"0","summary":"证券之星消息，近日派林生物披露，截至2024年11月29日公司股东户数为2.55万户，较11月20日增加282.0户，增幅为1.12%。户均持股数量由上期的2.9万股减少至2.87万股，户均持股市值为62.09万元。在生物制品行业个股中，派林生物股东户数低于行业平均水平，截至11月29日，生物制品行业平均股东户数为3.38万户。根据统计，派林生物2024年11月20日至2024年11月29日，主力资金净流出6588.37万元，游资资金净流入1183.31万元，散户资金净流入5405.06万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500028077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2488301671","title":"派林生物：11月29日高管杨莉减持股份合计14.81万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2488301671","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488301671?lang=zh_cn&edition=full","pubTime":"2024-12-02 21:40","pubTimestamp":1733146800,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月2日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2024年11月29日公司董事杨莉共减持公司股份14.81万股，占公司总股本为0.0203%。变动期间公司股价上涨1.69%，11月29日当日收盘报21.62元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200031879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2488679569","title":"派林生物(000403.SZ)部分股东合计完成减持263万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2488679569","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488679569?lang=zh_cn&edition=full","pubTime":"2024-12-02 21:25","pubTimestamp":1733145939,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)公告，公司股东杨峰、杨莉合计减持公司股份263万股，占总股本比例0.36%，本次股份减持计划已实施完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2487555416","title":"派林生物：11月28日高管杨莉减持股份合计68.26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487555416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487555416?lang=zh_cn&edition=full","pubTime":"2024-11-29 21:39","pubTimestamp":1732887559,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月29日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2024年11月28日公司董事杨莉共减持公司股份68.26万股，占公司总股本为0.0934%。变动期间公司股价下跌0.65%，11月28日当日收盘报21.26元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900041230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2486316886","title":"派林生物：11月27日高管杨莉减持股份合计94.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486316886","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486316886?lang=zh_cn&edition=full","pubTime":"2024-11-28 21:01","pubTimestamp":1732798868,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月28日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2024年11月27日公司董事杨莉共减持公司股份94.6万股，占公司总股本为0.1294%。变动期间公司股价上涨0.61%，11月27日当日收盘报21.4元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800036434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"gpt_icon":0},{"id":"2486602043","title":"派林生物(000403)11月20日股东户数2.52万户，较上期减少0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486602043","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486602043?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:02","pubTimestamp":1732784520,"startTime":"0","endTime":"0","summary":"证券之星消息，近日派林生物披露，截至2024年11月20日公司股东户数为2.52万户，较11月8日减少64.0户，减幅为0.25%。户均持股数量由上期的2.9万股减少至2.9万股，户均持股市值为65.43万元。在生物制品行业个股中，派林生物股东户数低于行业平均水平，截至11月20日，生物制品行业平均股东户数为3.4万户。根据统计，派林生物2024年11月8日至2024年11月20日，主力资金净流出3268.83万元，游资资金净流入592.07万元，散户资金净流入2676.76万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800026626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2486582928","title":"派林生物：11月26日高管杨莉减持股份合计34.48万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486582928","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486582928?lang=zh_cn&edition=full","pubTime":"2024-11-27 21:01","pubTimestamp":1732712466,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月27日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2024年11月26日公司董事杨莉共减持公司股份34.48万股，占公司总股本为0.0472%。变动期间公司股价下跌0.28%，11月26日当日收盘报21.27元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700037117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2486850081","title":"派林生物：11月22日高管杨莉减持股份合计50.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486850081","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486850081?lang=zh_cn&edition=full","pubTime":"2024-11-25 21:22","pubTimestamp":1732540939,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月25日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2024年11月22日公司董事杨莉共减持公司股份50.85万股，占公司总股本为0.0696%。变动期间公司股价下跌3.77%，11月22日当日收盘报21.45元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500031182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"gpt_icon":0},{"id":"2480235391","title":"华福证券：给予派林生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480235391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480235391?lang=zh_cn&edition=full","pubTime":"2024-11-03 15:56","pubTimestamp":1730620575,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华近期对派林生物进行研究并发布了研究报告《业绩持续稳健增长，新浆站验收助力长期发展》，本报告对派林生物给出买入评级，当前股价为22.19元。对应当前市值，2024-2026年PE分别为21/18/16X，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有15家机构给出评级，买入评级14家，增持评级1家；过去90天内机构目标均价为31.04。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110300001113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000403"],"gpt_icon":0},{"id":"2479082797","title":"中邮证券：给予派林生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479082797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479082797?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:21","pubTimestamp":1730380900,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司蔡明子,陈成近期对派林生物进行研究并发布了研究报告《业绩持续稳健增长，长期成长空间广阔》，本报告对派林生物给出买入评级，当前股价为22.39元。截至目前，派斯菲科已经完成全部19个浆站的验收开采，为未来几年派斯菲科采浆量的持续快速增长奠定坚实基础。最新盈利预测明细如下：该股最近90天内共有14家机构给出评级，买入评级13家，增持评级1家；过去90天内机构目标均价为31.04。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100044023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","161027"],"gpt_icon":0},{"id":"2479929887","title":"华源证券：给予派林生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479929887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479929887?lang=zh_cn&edition=full","pubTime":"2024-10-31 08:36","pubTimestamp":1730334975,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯,李强近期对派林生物进行研究并发布了研究报告《业绩稳健增长，期待大股东长期赋能空间》，本报告对派林生物给出买入评级，当前股价为22.27元。1）公司目前拥有38个浆站，在国内上市公司里面采浆站数量仅次于天坛生物和上海莱士；采浆量方面，公司已经进入千吨级血液制品第一梯队。最新盈利预测明细如下：该股最近90天内共有14家机构给出评级，买入评级13家，增持评级1家；过去90天内机构目标均价为31.04。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100012072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000403"],"gpt_icon":0},{"id":"2479244907","title":"万联证券：给予派林生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479244907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479244907?lang=zh_cn&edition=full","pubTime":"2024-10-30 14:35","pubTimestamp":1730270128,"startTime":"0","endTime":"0","summary":"万联证券股份有限公司黄婧婧近期对派林生物进行研究并发布了研究报告《点评报告：业绩表现稳健，控费水平提升》，本报告对派林生物给出买入评级，当前股价为22.25元。最新盈利预测明细如下：该股最近90天内共有12家机构给出评级，买入评级11家，增持评级1家；过去90天内机构目标均价为31.2。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000021009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000403"],"gpt_icon":0},{"id":"2479649593","title":"派林生物：10月28日召开业绩说明会，包括知名机构高毅资产的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479649593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479649593?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:42","pubTimestamp":1730162541,"startTime":"0","endTime":"0","summary":"全年来看，公司也将较好的完成年度经营业绩和采浆量目标。广东双林二期扩能预计 2025 年中投产，年产能将提升至 1500吨；派斯菲科也将于 2025年初扩能至年产能 1500吨。关于投浆计划，相比 2024年，2025年随着广东双林扩能投产和派斯菲科纤原产品集采中标，预计 2025 年因子类产品八因子、PCC和纤原产品产量和销售将同比增加，将推动公司吨浆净利润提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2478108617","title":"派林生物最新公告：两子公司获单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2478108617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478108617?lang=zh_cn&edition=full","pubTime":"2024-10-28 18:30","pubTimestamp":1730111444,"startTime":"0","endTime":"0","summary":"派林生物公告，公司全资子公司哈尔滨派斯菲科生物制药有限公司下属桦南县派斯菲科单采血浆有限公司和肇东市派斯菲科单采血浆有限公司收到黑龙江省卫生健康委员会签发的《单采血浆许可证》。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800025900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2478158742","title":"派林生物最新公告：前三季度净利润同比增长66.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478158742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478158742?lang=zh_cn&edition=full","pubTime":"2024-10-27 17:04","pubTimestamp":1730019849,"startTime":"0","endTime":"0","summary":"派林生物发布2024年第三季度报告，前三季度公司实现营业收入18.90亿元，同比增长37.49%；归属于上市公司股东的净利润5.43亿元，同比增长66.38%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700013343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403"],"gpt_icon":0},{"id":"2478377171","title":"派林生物(000403.SZ)发前三季业绩，净利润5.43亿元，同比增长66.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478377171","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478377171?lang=zh_cn&edition=full","pubTime":"2024-10-27 16:37","pubTimestamp":1730018225,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)发布2024年前三季度报告，报告期内公司实现营业收入18.90亿元，同比增长37.49%;归属于上市公司股东的净利润5.43亿元，同比增长66.38%;归属于上市公司股东扣除非经常性损益净利润4.98亿元，同比增长84.71%;基本每股收益0.7425元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000403"],"gpt_icon":0},{"id":"2474002858","title":"光大证券医药生物行业2025年投资策略：从支付视角挖掘投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2474002858","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474002858?lang=zh_cn&edition=full","pubTime":"2024-10-12 15:26","pubTimestamp":1728718018,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0010","BK4585","601788","LU2153592121.USD","600129","LU0359202008.SGD","000403","BK0276","BK1583","LU2488822045.USD","BK1222","LU2153591404.USD","LU2348774022.SGD","09996","LU1064130708.USD","600276","BK0071","LU0594300419.USD","LU1023057109.AUD","600161","000808.SH","06178","BK0146","SGXZ49509284.SGD","09997","399265","002550","BK0046","BK1574","BK4142","BK0113","BK0196","BK1100","LU2148510915.USD","688271","LU1969619763.USD","BK0028","LU1781817850.SGD","BK0082","IE0005HP3H50.USD","300760","LU2213484517.USD","LU1794554557.SGD","H","159883","163118","LU0594300179.USD","01801","002223"],"gpt_icon":0},{"id":"2474050430","title":"源达研究报告：血液制品行业盈利水平改善，未来成长空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2474050430","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474050430?lang=zh_cn&edition=full","pubTime":"2024-10-11 16:55","pubTimestamp":1728636900,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　血液制品属于生物制品行业的细分行业，主要以健康人血浆或经特异免疫的人血浆为原料，采用生物学工艺或分离纯化技术制备的生物活性制剂，是不可或缺的国家重要战略性储备物资及重大疾病急救药品。根据北京欧立信调研中心统计数据，2023年我国血液制品市场规模超500亿元，预计到2030年我国血液制品市场规模将达到950亿元。行业盈利水平显著改善。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2024-10-11/doc-incseqcx5094529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0071","BK0010","300294","BK0028","BK0239","BK0197","BK0188","BK0046","000403","BK0168","002880","BK0048","BK0196","002252","BK0082","600161","BK0185","BK0251","300318"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-06-28","address":"山西省太原市晋源区长兴南街8号阳光城环球金融中心3004室","stockEarnings":[{"period":"1week","weight":-0.0317},{"period":"1month","weight":-0.0568},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.2401},{"period":"1year","weight":-0.233},{"period":"ytd","weight":-0.2206}],"companyName":"派斯双林生物制药股份有限公司","boardCode":"AI0027","perCapita":"26897股","boardName":"医药制造业","registeredCapital":"73107万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":"　　派斯双林生物制药股份有限公司主营业务为血液制品的研究、开发、生产和销售，公司主要产品为人血白蛋白、静注人免疫球蛋白(pH4)、人免疫球蛋白、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、人凝血因子Ⅷ。","serverTime":1734686480362,"listedPrice":3.78,"stockholders":"25456人(较上一季度增加1.12%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派林生物,000403,派林生物股票,派林生物股票老虎,派林生物股票老虎国际,派林生物行情,派林生物股票行情,派林生物股价,派林生物股市,派林生物股票价格,派林生物股票交易,派林生物股票购买,派林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}